ALNY monthly performance report
Explore ALNY's monthly returns, drawdown, and seasonality trends — updated every month.
ALNY monthly report
—
Key takeaways
- Alnylam Pharmaceuticals (ALNY) closed November 2026 at $165.04, up 0.02% for the month and −63.65% over the trailing 12 months.
- Year-to-date, ALNY is −58.50%, underperforming the S&P 500 which has returned +10.62% YTD.
- The stock is trading −40.26% versus its 200-day moving average ($276.26), a cautious technical signal.
- Over the past three years, ALNY has underperformed the S&P 500 by −71.36%, with a relative strength index reading of 58.4.
- Win rate over the trailing 39 months stands at 43.6% — 17 positive months versus 22 negative months.
Alnylam Pharmaceuticals ended November 2026 at $165.04, posting a monthly return of +0.02%. The S&P 500 returned −0.18% over the same window, leaving relative performance at +0.20%.
The current quarter stands at −33.11% (Q4 2026 (QTD)), while medium-term trend remains soft: price is −40.26% versus the 200-day moving average ($276.26).
Year-to-date, ALNY is −58.50% against SPY +10.62%, a gap of −69.12%. The stock is currently −65.60% below its 52-week high, with maximum 3-year drawdown at −69.13%.
| Period | ALNY | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | +5.36% | −0.36% | +5.72% |
| 1 Week | +5.84% | +2.59% | +3.24% |
| 1 Month | +0.02% | −0.18% | +0.20% |
| 3 Months | −27.82% | −2.37% | −25.45% |
| 6 Months | −43.38% | +0.83% | −44.21% |
| YTD | −58.50% | +10.62% | −69.12% |
| 12 Months | −63.65% | +12.25% | −75.90% |
| 3 Years | +0.02% | +71.37% | −71.36% |
| Rank | Month | Return |
|---|---|---|
| #1 | Jun 2024 | +63.71% |
| #2 | Jul 2025 | +20.29% |
| #3 | Aug 2026 | +17.11% |
| #4 | May 2025 | +15.70% |
| #5 | Jan 2025 | +15.30% |
| Rank | Month | Return |
|---|---|---|
| #1 | Oct 2026 | −33.13% |
| #2 | Jul 2026 | −31.73% |
| #3 | Jan 2026 | −14.99% |
| #4 | Oct 2023 | −14.29% |
| #5 | Feb 2024 | −12.62% |
| Quarter | Return |
|---|---|
| Q3 2025 | +39.84% |
| Q4 2025 | −12.80% |
| Q1 2026 | −16.79% |
| Q2 2026 | −9.02% |
| Q3 2026 | −18.03% |
| Q4 2026 (QTD) | −33.11% |
| Year | Return |
|---|---|
| 2023 | −19.46% |
| 2024 | +22.94% |
| 2025 | +68.99% |
| 2026 | −58.50% |
| Metric | Value |
|---|---|
| 52-Week High | $479.79 (2025-12-03) |
| 52-Week Low | $149.18 (2026-11-10) |
| Current Price | $165.04 |
| 200-Day Moving Average | $276.26 |
| Price vs 200DMA | −40.26% |
| 3-Year Maximum Drawdown | −69.13% (2026-11-10) |
| Current Drawdown from 52W High | −65.60% |
| RS metric | Value |
|---|---|
| RS Index (3-year, rebased to 100) | 58.4 |
| 3-Year Excess Return vs S&P 500 | −71.36% |
| RS Peak | 197.8 (Sep 2025) |
| RS Trough | 53.9 (Nov 2026) |
| Status | Underperforming Benchmark |
Frequently asked questions
What was ALNY's return for this report period?
ALNY returned +0.02% in the latest monthly window ending 2026-11-13.
Has ALNY outperformed SPY year to date?
YTD ALNY: −58.50% vs SPY: +10.62%.
What is ALNY's 12-month return?
−63.65% over the trailing 12 months.
Is ALNY above or below its 200-day moving average?
Price is −40.26% versus 200DMA ($276.26).
What is the maximum drawdown in the 3-year window?
−69.13% on 2026-11-10.